Companies Taking Strategic Initiatives in Delivering Innovative Solutions to Boost Sales and Meet Customer Demands - Research Report on ResMed, Quest Diagnostics, Mettler-Toledo, Gilead, and TearLab

NEW YORK, June 7, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting ResMed Inc. (NYSE: RMD), Quest Diagnostics Inc. (NYSE: DGX), Mettler-Toledo International, Inc. (NYSE: MTD), Gilead Sciences, Inc. (NASDAQ: GILD), and TearLab Corporation (NASDAQ: TEAR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

ResMed Inc. Research Report

On June 3, 2013, ResMed Inc. (ResMed) launched the SleepSeeker Online Tool to increase patient engagement in therapy for sleep-disordered breathing. "We know that patient engagement can be a powerful force in improving compliance," said Susan de la Torre, Director, Channel Marketing for ResMed. She added, "SleepSeeker engages patients by providing encouragement and motivation to learn about their therapy and gives them the tools to become their own health advocates." SleepSeeker was introduced at "SLEEP 2013", the annual meeting of the Associated Professional Sleep Societies held in the first week of June 2013. The Full Research Report on ResMed Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/ba41_RMD]

--

Quest Diagnostics Inc. Research Report

On May 16, 2013, Quest Diagnostics Inc. (Quest) announced that it has acquired the toxicology and clinical laboratory business of medical center operator Concentra, a subsidiary of Humana Inc. In addition, Quest Diagnostics has entered into a long-term agreement with Concentra to be its primary provider of workplace drug toxicology and clinical laboratory testing. "With this transaction, Concentra's patients, physicians and employer clients will gain access to Quest's industry-leading menu of innovative workplace drug and clinical lab diagnostic information services," said Steve Rusckowski, President and Chief Executive Officer of Quest. "The transaction is also consistent with Quest's disciplined capital deployment strategy, which includes generating one to two percent in growth per year through strategically aligned fold-in acquisitions." Quest expects the transaction to be neutral to adjusted earnings per share in 2013 and modestly accretive to earnings per share in 2014. The Full Research Report on Quest Diagnostics Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/0cb6_DGX]

--

Mettler-Toledo International, Inc. Research Report

On May 23, 2013, Mettler-Toledo International Inc. (METTLER TOLEDO) announced the launch of its online newsroom, which offers a central location for industry and media experts to discover what's new at the worldwide supplier of precision instruments and other enabling technologies. "The newsroom is helping METTLER TOLEDO bring helpful content to its customers and industries using social- and multi-media tools alongside its more traditional communications vehicles," said Marie-Louise Hupert, METTLER TOLEDO's e-Program Manager. According to the Company, visitors can search archives and decide how they want to access METTLER TOLEDO literature based on individual preferences. Media professionals can also access news via a custom search or catalogue entries organized by product and industry. Ms. Hupert added, "Our goal with the streamlined access point is to make their lives easier." The Full Research Report on Mettler-Toledo International, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/a364_MTD]

--

Gilead Sciences, Inc. Research Report

According to a Bloomberg report dated June 3, 2013, Hepatitis C research has currently turned into one of the fastest-developing areas in medicine. Hepatitis C is an infectious disease that can scar the liver and afflicts about 170 million people worldwide. New to the Hepatitis C market, Gilead Sciences, Inc. (Gilead) filed for regulatory clearance for a drug known as sofosbuvir in April 2013. According to average estimates compiled by Bloomberg, the pill may reach sales of almost $4 billion in 2015 and $6.3 billion in 2016. The Company's stock has more than doubled in the past year on optimism about the pill. Bloomberg also reported that Hepatitis C drugs like sofosbuvir may spawn compulsory generics in countries that can't afford them. As per Mark Schoenebaum, an analyst at ISI Group in New York, the sofosbuvir drug may cost as much as $100,000 per patient. The Foster City, California-based company gained the drug with its $11.1 billion acquisition of Pharmasset Inc. in year 2012. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/9696_GILD]

--

TearLab Corporation Research Report

On May 13, 2013, TearLab Corp. (TearLab) reported its consolidated financial results for the Q1 2013. The Company reported revenues of $2.5 million, reflecting a significant increase of 486.5% YoY. The Company's net loss was approximately $8.6 million, or $0.30 per share, compared to a net loss of $9.1 million or $0.44 per share in Q1 2012. "We started 2013 with strong system orders and a solid launch of our new Masters program," said Elias Vamvakas, TearLab's Chief Executive Officer. "While our revenue growth highlights our continuing success in building a recurring revenue base, like in previous quarters, our strong sales performance was not fully reflected in our Q1-2013 financial results due to the traditional lag between access program contract signing and product shipment, and to our current system manufacturing back-order position. Moving forward, driven by the success of our sales and marketing programs, and by strong showings at key events like ASCRS, we expect to see this positive momentum continue through the year." The Full Research Report on TearLab Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at [http://www.wsreports.com/r/full_research_report/53d7_TEAR]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquires, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports